Latest Genetic Signatures News

BCAL Diagnostics has completed clinical validation for BREASTESTplus 2 across all breast densities and is targeting a November launch, while expanding Avantect Multicancer access. The commercial push comes alongside $1.895 million in quarterly operating cash outflows, only $580,000 in cash at quarter end and a growing strategic stake in Genetic Signatures.

Genetic Signatures has added a new AGM resolution seeking approval to issue up to 340.7 million shares and 129.7 million options under its proposed Microba merger. The all-scrip transaction remains non-binding and subject to further shareholder, court, regulatory and due diligence conditions.

Genetic Signatures and Microba Life Sciences have agreed in principle to revise their proposed merger, reducing Microba shareholders’ post-deal ownership from about 67% to 60%. The change improves the position of existing GSS shareholders, but the transaction remains non-binding and subject to multiple approvals.

Microba has secured a $2.025 million placement while cutting costs further, launching GI Navigator and advancing its proposed merger with Genetic Signatures. The funding comes as the company reports strong Australian testing growth but only about one quarter of cash cover before the raise.

Genetic Signatures says its existing directors will resign if BCAL nominees become a majority after the 28 October EGM. The company is also demanding clarity on whether BCAL intends to merge with GSS, pointing to the stark difference between the two companies’ cash runways.

Genetic Signatures reduced its quarterly operating cash outflow to A$1.0 million after restructuring, while commercial testing began under its Danish hospital contract. The company is also advancing an all-scrip Microba merger, but faces a contested shareholder meeting later this month.

Microba shareholders would own about 67% of an enlarged Genetic Signatures under a proposed all-scrip merger valued at approximately A$51 million. The deal combines roughly A$29.6 million of FY2026 revenue and identifies up to A$3 million in potential annual cost synergies, but remains subject to a long list of approvals.

Microba Life Sciences delivered a mixed FY26, with overall revenue slipping 5.8% to $14.76 million and a statutory loss widening 38.7% to $20.7 million. The company’s strategic pivot to core microbiome testing paid off with a 92% surge in core testing revenue and record test volumes in Australia and the UK. Despite the headline loss, underlying loss improved 11% thanks to cost cuts and AI-driven efficiencies. Microba is gearing up for the October launch of its GI Navigator diagnostic and targeting cash flow break-even on a run-rate basis in calendar 2027.

Genetic Signatures (ASX: GSS) and Microba Life Sciences (ASX: MAP) are in early talks about merging to form a larger infectious disease diagnostics entity, combining rapid pathogen detection with microbiome profiling. The proposed group would have FY2026 pro forma revenue of around A$29 million and a stronger financial footing.

BCAL Diagnostics has increased its shareholding in Genetic Signatures to nearly a fifth, aiming to leverage infectious disease technology to complement its cancer detection portfolio.

Genetic Signatures narrowed its FY2026 net loss by 30% to $14 million amid a strategic overhaul, signing a key 10-year supply deal with Denmark’s Hvidovre Hospital and resetting its US market approach.

BCAL Diagnostics has strengthened its leadership, advanced breast cancer detection tests, and secured key funding and strategic investments to underpin its FY2027 growth plans.